<?xml version="1.0" ?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:media="http://search.yahoo.com/mrss/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:seo="http://purl.org/seo/elements/1.0/" version="2.0">
	<channel>
		<title>TMX Newsfile Pharmaceuticals News Releases</title>
		<link>https://feeds.newsfilecorp.com/industry/medical-pharmaceuticals</link>
		<description>Last 10 Pharmaceuticals news releases from TMX Newsfile. Contact us for a custom full-bodied RSS feed complete with exchange and ticker data.</description>
		<language>en</language>
		<copyright>CopyRight (c) 2026, Newsfile Corp. All Rights Reserved.</copyright>
		<managingEditor>office@newsfilecorp.com (Newsfile Corp.)</managingEditor>
		<webMaster>office@newsfilecorp.com (Newsfile Corp.)</webMaster>
		<lastBuildDate>Tue, 09 Jun 2026 03:01:12 -0400</lastBuildDate>
		<image>
			<url>https://www.newsfilecorp.com/images/tmx-newsfile-wire-logo.png</url>
			<title>TMX Newsfile Pharmaceuticals News Releases</title>
			<link>https://feeds.newsfilecorp.com/industry/medical-pharmaceuticals</link>
		</image>
		<atom:link rel="self" type="application/rss+xml" href="https://feeds.newsfilecorp.com/industry/medical-pharmaceuticals"/>
		<item xml:lang="en">
			<title>Herbal Dispatch Completes 452kg Multi Client Medical Cannabis Export Shipment To Europe</title>
			<link>https://www.newsfilecorp.com/release/300675/Herbal-Dispatch-Completes-452kg-Multi-Client-Medical-Cannabis-Export-Shipment-To-Europe</link>
			<description>&lt;img src="https://api.newsfilecorp.com/newsinfo/300675/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;Vancouver, British Columbia--(Newsfile Corp. - June 9, 2026) - Herbal Dispatch Inc.  (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis commerce and international distribution platform, is pleased to announce the successful completion of a 452-kilogram international medical cannabis export shipment to several customers in Germany.While the shipment represents an important operational milestone, its greater significance lies in the fact that one shipment was...</description>
			<pubDate>Tue, 09 Jun 2026 03:01:00 -0400</pubDate>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/300675/Herbal-Dispatch-Completes-452kg-Multi-Client-Medical-Cannabis-Export-Shipment-To-Europe</guid>
		</item>
		<item xml:lang="en">
			<title>CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers</title>
			<link>https://www.newsfilecorp.com/release/300420/CBIH-Advances-Strategic-Pathway-to-Bring-VitaCookies-ScienceDriven-Functional-Wellness-Platform-to-Texas-Consumers</link>
			<description>&lt;img src="https://api.newsfilecorp.com/newsinfo/300420/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;Houston, Texas--(Newsfile Corp. - June 8, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public biotechnology company trading under the ticker symbol CBIH, today announced that it has completed and submitted the required documentation as part of its Texas licensing process related to the planned commercialization of VitaCookies, its cannabinoid-formulated functional wellness cookie line. CBIH intends to move forward carefully, with a focus on licensing and franchising...</description>
			<pubDate>Mon, 08 Jun 2026 07:00:00 -0400</pubDate>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/300420/CBIH-Advances-Strategic-Pathway-to-Bring-VitaCookies-ScienceDriven-Functional-Wellness-Platform-to-Texas-Consumers</guid>
		</item>
		<item xml:lang="en">
			<title>BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors</title>
			<link>https://www.newsfilecorp.com/release/300463/BioGene-Therapeutics-Inc.-Appoints-Ty-Howton-to-Board-of-Directors</link>
			<description>&lt;img src="https://api.newsfilecorp.com/newsinfo/300463/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;Vancouver, British Columbia--(Newsfile Corp. - June 8, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) ("PreveCeutical"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, today announced that BioGene Therapeutics Inc. (the "Company"or 'BioGene"), a company that is a significant shareholder of, has appointed Ty Howton to BioGene's Board of Directors, effective immediately....</description>
			<pubDate>Mon, 08 Jun 2026 03:00:00 -0400</pubDate>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/300463/BioGene-Therapeutics-Inc.-Appoints-Ty-Howton-to-Board-of-Directors</guid>
		</item>
		<item xml:lang="en">
			<title>Custom Health Holdings Inc. Announces Completion of Plan of Arrangement</title>
			<link>https://www.newsfilecorp.com/release/300415/Custom-Health-Holdings-Inc.-Announces-Completion-of-Plan-of-Arrangement</link>
			<description>&lt;img src="https://api.newsfilecorp.com/newsinfo/300415/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;Vancouver, British Columbia--(Newsfile Corp. - June 5, 2026) - Custom Health Holdings Inc. (formerly, Queue Ventures Ltd.) ("Custom Health" or the "Company"), further to its press release dated May 13, 2026, is pleased to announce the successful completion of its previously announced plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement") with Custom Health, Inc. ("Custom Delaware"), pursuant to which, among other things, Custom Health has acquired 100% of...</description>
			<pubDate>Fri, 05 Jun 2026 18:00:00 -0400</pubDate>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/300415/Custom-Health-Holdings-Inc.-Announces-Completion-of-Plan-of-Arrangement</guid>
		</item>
		<item xml:lang="en">
			<title>Telescope Innovations Founder and CTO, Professor Jason Hein, Receives 2026 SCI Canada LeSueur Memorial Award</title>
			<link>https://www.newsfilecorp.com/release/300261/Telescope-Innovations-Founder-and-CTO-Professor-Jason-Hein-Receives-2026-SCI-Canada-LeSueur-Memorial-Award</link>
			<description>&lt;img src="https://api.newsfilecorp.com/newsinfo/300261/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;Vancouver, British Columbia--(Newsfile Corp. - June 5, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company") congratulates its Founder and Chief Technology Officer, Professor Jason Hein, on receiving the 2026 SCI Canada LeSueur Memorial Award from the Society of Chemical Industry ("SCI").Figure 1. The 2026 LeSeueur Memorial Award Presented to Professor Jason HeinTo view an enhanced version of this graphic, please...</description>
			<pubDate>Fri, 05 Jun 2026 08:00:00 -0400</pubDate>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/300261/Telescope-Innovations-Founder-and-CTO-Professor-Jason-Hein-Receives-2026-SCI-Canada-LeSueur-Memorial-Award</guid>
		</item>
		<item xml:lang="en">
			<title>InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements</title>
			<link>https://www.newsfilecorp.com/release/300271/InMed-Pharmaceuticals-Regains-Compliance-with-Nasdaq-Continued-Listing-Requirements</link>
			<description>&lt;img src="https://api.newsfilecorp.com/newsinfo/300271/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;Vancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on June 3, 2026 informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on Nasdaq.As previously disclosed, the Company was notified by Nasdaq...</description>
			<pubDate>Thu, 04 Jun 2026 17:00:00 -0400</pubDate>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/300271/InMed-Pharmaceuticals-Regains-Compliance-with-Nasdaq-Continued-Listing-Requirements</guid>
		</item>
		<item xml:lang="en">
			<title>TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally</title>
			<link>https://www.newsfilecorp.com/release/300055/TempraMed-Signs-Agreement-for-Exclusive-Distribution-Partnership-in-Brazil-One-of-the-Largest-Diabetes-and-Biologics-Markets-Globally</link>
			<description>&lt;img src="https://api.newsfilecorp.com/newsinfo/300055/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;HighlightsTempraMed signs Agreement for exclusive distribution in Brazil with Mobil Saúde Comercial Ltda Brazil represents one of the world's largest markets for diabetes, GLP-1 therapies, and temperature-sensitive biologics1.  Diabetes market alone reached USD $2.15 Billion in 2025 Partnership builds on TempraMed's recently granted Brazilian patent protecting the VIVI Box™ platform Expands TempraMed's commercialization footprint across Latin America following recent regional expansion...</description>
			<pubDate>Thu, 04 Jun 2026 07:00:00 -0400</pubDate>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/300055/TempraMed-Signs-Agreement-for-Exclusive-Distribution-Partnership-in-Brazil-One-of-the-Largest-Diabetes-and-Biologics-Markets-Globally</guid>
			<atom:subtitle>Expands Latin America presence with strategic partnership with Mobil Saúde and builds on TempraMed's recently granted Brazilian patent portfolio</atom:subtitle>
		</item>
		<item xml:lang="en">
			<title>Theralase(R) Lists Warrants on the TSXV</title>
			<link>https://www.newsfilecorp.com/release/299901/TheralaseR-Lists-Warrants-on-the-TSXV</link>
			<description>&lt;img src="https://api.newsfilecorp.com/newsinfo/299901/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;Toronto, Ontario--(Newsfile Corp. - June 3, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted for listing up to 20,399,050 common share purchase warrants of the Company ("Warrants"),...</description>
			<pubDate>Wed, 03 Jun 2026 07:00:00 -0400</pubDate>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/299901/TheralaseR-Lists-Warrants-on-the-TSXV</guid>
		</item>
		<item xml:lang="en">
			<title>Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors</title>
			<link>https://www.newsfilecorp.com/release/299920/Defence-Therapeutics-Appoints-Seasoned-Biopharmaceutical-Executive-Dr-John-Beaver-to-Its-Board-of-Directors</link>
			<description>&lt;img src="https://api.newsfilecorp.com/newsinfo/299920/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;Montreal, Quebec--(Newsfile Corp. - June 3, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Beaver to its Board of Directors. Dr. Beaver brings more than two decades of leadership experience across global pharmaceutical and biotechnology organizations.Dr. Beaver has held senior leadership positions at several...</description>
			<pubDate>Wed, 03 Jun 2026 03:15:00 -0400</pubDate>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/299920/Defence-Therapeutics-Appoints-Seasoned-Biopharmaceutical-Executive-Dr-John-Beaver-to-Its-Board-of-Directors</guid>
		</item>
		<item xml:lang="en">
			<title>Herbal Dispatch Inc. Appoints Jason Spatafora as Strategic Advisor</title>
			<link>https://www.newsfilecorp.com/release/299946/Herbal-Dispatch-Inc.-Appoints-Jason-Spatafora-as-Strategic-Advisor</link>
			<description>&lt;img src="https://api.newsfilecorp.com/newsinfo/299946/156" id="156" width="2" height="2" style="width: 1px;  height: 1px;border: 0px solid;" /&gt;Vancouver, British Columbia--(Newsfile Corp. - June 3, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a leading cannabis e-commerce and distribution platform, is pleased to announce the appointment of Jason Spatafora as a strategic advisor to the Company.The appointment comes as Herbal Dispatch continues its transformation into a scalable, technology-enabled cannabis distribution platform. The Company's proprietary technology...</description>
			<pubDate>Wed, 03 Jun 2026 03:01:00 -0400</pubDate>
			<guid isPermaLink="true">https://www.newsfilecorp.com/release/299946/Herbal-Dispatch-Inc.-Appoints-Jason-Spatafora-as-Strategic-Advisor</guid>
		</item>
	</channel>
</rss>
